Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marina Y. Konopleva"'
Autor:
Nicholas J. Short, Faustine Ong, Farhad Ravandi, Graciela M. Nogueras Gonzalez, Tapan M. Kadia, Naval G. Daver, Courtney D DiNardo, Marina Y Konopleva, Gautam Borthakur, Betul Oran, Gheath Al-Atrash, Rohtesh S Mehta, Elias J. Jabbour, Musa Yilmaz, Ghayas C. Issa, Abhishek Maiti, Richard E Champlin, Hagop M Kantarjian, Elizabeth J Shpall, Uday R. Popat
Publikováno v:
Blood Advances.
Although venetoclax-based lower-intensity regimens have greatly improved outcomes for older adults with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy, the optimal induction for older patients with newly diagnosed AML who are s
Autor:
Alexandre Bazinet, Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang, Sanam Loghavi, Jeffrey L Jorgensen, Keyur P Patel, Courtney D DiNardo, Naval G. Daver, Yesid Alvarado, Fadi G. Haddad, Sherry R Pierce, Graciela M Nogueras Gonzalez, Abhishek Maiti, Koji Sasaki, Musa Yilmaz, Philip A Thompson, William G. Wierda, Guillermo Garcia-Manero, Michael Andreeff, Elias J. Jabbour, Marina Y. Konopleva, Xuelin Huang, Hagop M Kantarjian, Farhad Ravandi
Publikováno v:
Blood Advances.
Acute myeloid leukemia (AML) can be treated with either high or low-intensity regimens. Highly sensitive assays for measurable residual disease (MRD) now allow for a more precise assessment of response quality. We hypothesized that treatment intensit
Autor:
Elyse A Olesinski, Karanpreet S Bhatia, Aarthi Nivasini Mahesh, Shazwina Rosli, Jameelah S Mohamed, Wei Ying Jen, Nitin Jain, Jacqueline S. Garcia, Gee Chuan Wong, Melissa G Ooi, Anthony Letai, Marina Y. Konopleva, Shruti Bhatt
Publikováno v:
Blood Advances.
Autor:
Hussein A, Abbas, Hanxiao, Sun, Sherry R, Pierce, Rashmi, Kanagal-Shamanna, Ziyi, Li, Musa, Yilmaz, Gautam, Borthakur, Adam J, DiPippo, Elias J, Jabbour, Marina Y, Konopleva, Nicholas J, Short, Courtney D, DiNardo, Naval G, Daver, Farhad, Ravandi, Tapan M, Kadia
Publikováno v:
Blood advances.
Autor:
Chong Chyn Chua, Danielle Hammond, Andrew Kent, Ing Soo Tiong, Marina Y. Konopleva, Daniel A. Pollyea, Courtney D. DiNardo, Andrew H. Wei
Publikováno v:
Blood advances. 6(13)
The clinical benefit of adding venetoclax (VEN) to hypomethylating agents or low-dose cytarabine in older and/or unfit patients with newly diagnosed acute myeloid leukemia (AML) has been confirmed in phase 3 studies. With the increased uptake of VEN-